

References

- **Affandi B (1998):** An integrated analysis of vaginal bleeding pattern in clinical trials of implanon. Contraception. 58 : 99.
- **Anderson K, Odland V and Rybo G(1994):** Levonorgestrel-releasing and copper –releasing IUDs during five years of use: randomized comparative trial. Contraception 49(1): 56.
- **Apgar B and Greenberg G (2000):** Using progestins in clinical practice. American Family Physician. 62(8):15.
- **Baird DT, Cameron ST, Critchley HOD et al. (1996):** Prostaglandins and menstruation. Eur. J. Obstet. Gynecol. Prod. Biology. 70:15.
- **Baird DT(1997):** Amenorrhea. Lancet 350:275.
- **Barbieri RL, and Ryan KJ. (1995):** The menstrual cycle in Kistner's Gynecology principles and practices. Ryan KJ, Berkowitz RS and Barbieri RL. (Eds) 6th Edition. Mosby, Boston, Philadelphia. p 11.

- **Berga SL, Daniels TL and Giles DE (1997):** Women with functional hypothalamic amenorrhea but not other forms of anovulation display amplified cortisol concentrations. *Fertil. Steril.* 67:1024.
- **Brill SR and Rosenfeld WD (2000):** Contraception. *Medical Clinics of North America.* 84(4) :23
- **Burkman RT (1996):** Intrauterine devices and pelvic inflammatory disease: Evolving perspectives on the data. *Obstet. Gynecol. Surv.* 51: 35.
- **Cameron IT (2001):** The levonorgestrel intrauterine system: the benefits of reduced bleeding. *Eur. j. Contracept. Reprod. Health Care.* 1:27.
- **Cerel-SUHL SL (1999):** Update on oral contraceptive pills. *Am. Family Physician.* 60:2073.
- **Coutinho EM, Athayde C, Dantas C et al. (1999):** Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. *Contraception.* 59:115
- **Crosignani PG, Vercellini P, Mosconi P et al. (1997):** Levonorgestrel-releasing intrauterine device versus

hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. *Obstet. Gynecol.* 90:257.

- **Dardano KL and Burkman RT (1999):**The intrauterine contraceptive device: An often-forgotten and maligned method of contraception. *Am. J. Obstet. Gynecol.* 181:1.
- **Davis AJ (2000):**Advances in contraception. *Obstet. Gynecol. Clinics.* 27(3) :245.
- **Diaz S, Zepeda A, Maturana X et al. (1997):** Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding patterns during use of progesterone vaginal rings, progestin-only pills, norplant implants, and copper T 380-A intrauterine devices. *Contraception.* 56:223.
- **Dittrich R, Parker L, Rosen J et al. (2002):**Transdermal contraception: Evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. *Am. J. Obstet. Gynecol.* 186 (1) :33.

- **Espey LL, Tanaka N, Stacy S et al. (1992):** Inhibition of ovulation in the gonadotropin-primed immature rat by exogenous prostaglandin E2. Prostaglandins. 43:67
- **Farley TMM, Rosenberg MJ, Rowe PJ et al. (1992):** Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet. 339:785.
- **Faundes D, Bahamondes L, Faundes A et al. (1995):** T-shaped IUDs move vertically with endometrial growth and involution during the menstrual cycle. Contraception. 57:413.
- **Fotherby K (1995):** Levonorgestrel: Clinical pharmacokinetic . Clin. Pharmacok. 28:203
- **Frankovich RJ, and Lebrun CM (2000):** Menstrual cycle, contraception and performance. Clinics in Sports Med. 19 (2) : 679.
- **Fraser IS (1992):** Prostaglandins, prostaglandin inhibitors and their roles in gynecological disorders. Baillieres Clin. Obstet. Gynecol. 6:829.

- **Fraser IS and Dennerstein GJ (1994):** Depo-Provera use in an Australian metropolitan practice. *Med. J.* 160:553.
- **Fraser IS, Weisberg E, Minehan E et al. (2000):** A detailed analysis of menstrual blood loss in women using norplant and nestorone progesterone only contraceptive implants or vaginal rings. *Contraception.* 61 (4):241.
- **Greydanus DE, Pate DR, Rimsza ME (2001):** Contraception in the adolescent: An update. *Pediatrics.* 107(3):166.
- **Grow DR and Shafeeq A (2000) :** New contraceptive methods. *Obstet. Gynecol. Clinics.* 27 (4) 233.
- **Hoper MM, Voelkel NF, Bates TO et al. (1997):** Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. *Am. J. Respir. Cell. Mol. Biol.* 17:748.
- **Jirecek S, Kink E, Wenzl R et al. (1998):** Hormonal eitiology of secondary amenorrhea .*Wien. Klin. Wochenschr.* 26; 110(12): 441.

- **Kaunitz AM (2000):** Injectable contraception new and existing options . Obstet. Gynecol. Clinics. 27 (4) 65.
- **Kim-Bjorklund T, Landgren BM and Johannisson E (1997):** Morphometric studies of the endometrium, the fallopian tubes and the corpus luteum during contraception with the 300 µg norethisterone (NET) minipill. Contraception.43:459.
- **Kim J, Wang J, Bambra C et al. (1999):** Expression of cyclooxygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy. Endocrinology. 140 (6): 2672.
- **Marshall LA (1994):** Clinical evaluation of amenorrhea in active and athletic women. Clin. Sports Med. 2:37.
- **Mastrioanni LJR (1997):** No evidence to support IUD and embryo destruction . Am. J. Obstet. Gynecol. 177:980.
- **McIver B, Romanski SA and Nippoldt TB (1997):** Evaluation and management of amenorrhea. Mayo. Clinic. Proc. 72:1161.

- **Meckstroth KR and Darney PD (2000):** Implantable contraception. *Obstet. Gynecol. Clinics.* 27 (4):865.
- **Miceli F, Minici F, Pardo MG et al. (2001) :** Endothelins enhance prostaglandins (PGE₂ and PGF_{2α}) biosynthesis and release by human luteal cells: evidence of a new paracrine/autocrine regulation of luteal function. *J. Clin. Endocrin. & Metab.* 86(2): 811.
- **Miller L (1998):** A double- blind study comparing the contraceptive efficacy, acceptability and safety of two progesterone only pills. *Eur. J. Contraception Reproductive Health Care.* 3(4) : 169.
- **Milne SA, Perchick C, Boddy SC and Jabbour HN (2001):** Expression, localization, and signaling of PGE₂ and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle. *The J. of Clin. Endocrinol. Metabol.* 86(9):4453.
- **Mishell DR, Bell JH, Good RG et al. (1996):** The intrauterine device: A bacteriologic study of the

endometrial cavity. Am. J. Obstet. Gynecol. 96:119.

- **Munro M (2000):** Medical management of abnormal uterine bleeding. Obstet. Gynecol. Clin. 27 (2)205.
- **Nelson AL (1996):** Counseling issues and management of side effects for women using depot medroxyprogesterone. contraception. J. Reprod. Med. 41(5) : 391.
- **Nelson AL (2000):** The intrauterine contraceptive device. Obstet. Gynecol. Clinics. 27(4) :1345
- **Ortiz ME, Croxatto HB and Bardin CW (1996):** Mechanisms of action of intrauterine devices. Obstet. Gynecol. Surv. 51(Suppl): 42.
- **Pletcher JR and Slap GB (1999):** Menstrual disorders: Amenorrhea. Pediatric Clinics of North America. 46 (3) : 505.
- **Poruondo JT, Tejada RF and Beneto JA (1995):** Values of endoscopy in gynecology . Endoscopy. 14(6):209.

- **Reisman H, Martin D and Michael J (2000):** A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 µg levonorgestrel with 20 µg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. *Am. J. Obstet. Gynecol.* 181(5):45.
- **Rivera R, Yacobson I and Grimes D (1999):** The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. *Am. J. of Obstet. Gynecol.* 181(5):1546.
- **Saleem S, Hills FA, Salem HT et al.(1996):** Mechanism of action of the intrauterine device: evidence for a specific biochemical deficiency in the endometrium. *Hum. Reprod.* 11:1220.
- **Scherzer WJ and McClamrock (1996):** Amenorrhea . In Novak's gynecology, 12th edition. Berek JS, Adashi EY and Hillard PA (eds). Williams and Wilkins. Baltimore, Philadelphia and Hong Kong. p 809.

- **Schrager S (2002):** Abnormal uterine bleeding associated with hormonal contraception. *Contraception*. 55:23
- **Singh M, Saxena BB, Raghubanshi RS et al. (1997):** Biodegradable norethindrone (NET: cholesterol) contraceptive implants. Phase II-A. a clinical study in women. *Contraception*. 55:23.
- **Sivin I, Viegas O, Campodonico I et al. (1997):** Clinical performance of a new two-rod levonorgestrel contraceptive implant: A three-year randomized study with Norplant implants as controls. *Contraception*. 55:73.
- **Smith SK, Abel MH, Kelly RW et al. (1981):** Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. *Br. J. Obstet. Gynaecol.* 88:434.
- **Song JY, Fraser IS and Mutie SY (1995):** Effect of progestagens on human endometrium. *Obstet. Gynecol. Surv.* 50:385.
- **Speroff L, Glass R and Kase N (1999):** Prostaglandins in Clinical Gynecologic Endocrinology and

Infertility. 6th Ed. Williams & Wilkins. Baltimore, Philadilphia and Hong Kong. p 460.

- **Speroff L and Jensen JT (2000):**Health benefits of oral contraceptives. *Obstet Gynecol Clin.* 27(4) :897.
- **Spinnato JA (1997):** Mechanism of action of intrauterine contraceptive devices and its relation to informed consent. *Am. J. Obstet. Gynecol.* 176:503.
- **Taneeapanichskul S, Intaraprasert S, Theppisai U et al.(2001):** Bone mineral density during long-term treatment with norplant implants and depot medroxyprogesterone acetate: A cross-sectional study of Thailand women. *Contraception.* 56:153
- **Thorneycroft IH (1994):** Amenorrhea. in *Current; Obestatric and gynecologic diagnosis and treatment .DeCherney AH and Pernoll ML (eds).* 8th edi. Appelton & Lange.Norwalk,Connecticut. p 1007.
- **Thorneycroft IH (1999):** Cycle control with oral contraceptives: A review of the literature. *Am. J. Obstet. Gynecol.* 180(2):280.

- **Vesce F, Jorrizzo G, Bianciotto et al. (2000):** Use of the copper intrauterine device in the management of secondary amenorrhea. *Fertil. Steril.* 73 (1): 162.
- **Warren M, Biller K and Shangold M (1999):** A new clinical option for hormone replacement therapy in women with secondary amenorrhea: Effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. *Am. J. Obstet. Gynecol.* 180 (1): 35.
- **Warren MP, Voussoughian F, Geer EB et al. (1999):** Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. *J. Clin. Endocrinol. Metabol.* 84:873.
- **Wenzl R, van Beek A, Schnabel P et al (1998):** Pharmacokinetics of etonogestrel released from the contraceptive implant implanon. *Contraception* 58:283.
- **William FG(1994):** Physiology of reproduction in women. In *Current Obstetric& Gynecologic*

Diagnosis & Treatment. DeCherney AH and Pernoll ML (eds). 8th ED. Appleton & Lange. Norwalk, Connecticut. p 124.

- **Williams TJ and Krahenbuhl GS(1997):** Menstrual cycle phase and running economy. Med. Sci. Sports Exerc. 29:1609.
- **World Health Organization Scientific Group (1987):** Mechanism of action, safety and efficacy of intrauterine devices. Geneva: World Health Organization; 1987. Technical Report Series No: 753.
- **World Health Organization (1997):** Technical Report series 735. Mechanism of action safety and efficacy of intrauterine devices. Geneva: World Health Organization.
- **World Health Organization (1998):** Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: Results of an international,

multicenter, case-control study. *Contraception*. 57:315.

- **Zhu M, Lei Z and Yang D (1999):** Evaluation of safety in Chinese women with amenorrhea following injection of depot-medroxyprogesterone for contraception. *Chin. J. Obstet. Gynecol.* 34(10): 621.